Latest C-peptide Stories
Using Mendelian randomization, Roman Pfister of the University of Cambridge, UK and colleagues demonstrate a potentially causal link between low levels of B-type natriuretic peptide (BNP), a hormone released by damaged heart tissue, and the development of type 2 diabetes.
Researchers may have found a specific dietary pattern linked to levels of C-peptide concentrations that increase a woman's risk for colorectal cancer.
ROCKVILLE, Md., June 28, 2011 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, announced the publication in The Lancet of results from Protege, a Phase 3 clinical study of teplizumab in type 1 diabetes.
LA JOLLA, Calif., June 24, 2011 /PRNewswire/ -- Cebix Incorporated announced today that preclinical data for its long-acting form of C-peptide, Ersatta(TM) (CBX129801), demonstrated a half-life of three days as compared to one hour for native C-peptide.
HYDERABAD, India, June 22, 2011 /PRNewswire/ -- Neuland Laboratories Ltd., a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract research and manufacturing services to customers located in 85 countries, today announced it will unveil its expanded capabilities for synthetic peptide manufacture at the 22nd American Peptide Symposium to be held in San Diego June 25-30, 2011.
CRANBURY, N.J., June 21, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced today that the U.S. Patent and Trademark Office issued U.S. Patent No.
LA JOLLA, Calif., June 16, 2011 /PRNewswire/ -- Cebix Incorporated announced today it is advancing the development of modified C-peptide for the treatment of complications of diabetes.
- A transitional zone between two communities containing the characteristic species of each.